179 related articles for article (PubMed ID: 22083191)
1. [High-throughput screening method of KRAS mutations at codons 12 and 13 in formalin-fixed paraffin-embedded tissue specimens of metastatic colorectal cancer].
Fukushima Y; Yanaka S; Murakami K; Abe Y; Koshizaka T; Hara H; Samejima C; Kishi Y; Kaneda M; Yoshino T
Gan To Kagaku Ryoho; 2011 Nov; 38(11):1825-35. PubMed ID: 22083191
[TBL] [Abstract][Full Text] [Related]
2. Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffin-embedded tissue specimens.
Laosinchai-Wolf W; Ye F; Tran V; Yang Z; White R; Bloom K; Choppa P; Labourier E
J Clin Pathol; 2011 Jan; 64(1):30-6. PubMed ID: 21030527
[TBL] [Abstract][Full Text] [Related]
3. High sensitivity of reverse-hybridization methodology in the detection of KRAS mutations from formalin-fixed paraffin-embedded colorectal cancer samples.
De Miglio MR; Mura A; Uras MG; Manca A; Contini M; Murgia L; Zinellu A; Sotgia S; Carru C; Massarelli G; Cossu-Rocca P
Diagn Mol Pathol; 2010 Dec; 19(4):201-8. PubMed ID: 21052001
[TBL] [Abstract][Full Text] [Related]
4. Detection of KRAS codon 12 and 13 mutations by mutant-enriched PCR assay.
Chang YS; Er TK; Lu HC; Yeh KT; Chang JG
Clin Chim Acta; 2014 Sep; 436():169-75. PubMed ID: 24863805
[TBL] [Abstract][Full Text] [Related]
5. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
6. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
7. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
Peeters M; Douillard JY; Van Cutsem E; Siena S; Zhang K; Williams R; Wiezorek J
J Clin Oncol; 2013 Feb; 31(6):759-65. PubMed ID: 23182985
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of the correlation with KRAS gene mutation status and the benefit of cetuximab plus irinotecan as third- line chemotherapy for the Treatment of unresectable metastatic colorectal cancer].
Asai H; Shinozaki E; Nozaki A; Watanabe T; Suenaga M; Matuzaka S; Chin K; Mizunuma N; Yasukawa M; Hatake K
Gan To Kagaku Ryoho; 2011 Aug; 38(8):1285-91. PubMed ID: 21829065
[TBL] [Abstract][Full Text] [Related]
9. Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach.
Carotenuto P; Roma C; Rachiglio AM; Tatangelo F; Pinto C; Ciardiello F; Nappi O; Iaffaioli RV; Botti G; Normanno N
Pharmacogenomics; 2010 Aug; 11(8):1169-79. PubMed ID: 20712532
[TBL] [Abstract][Full Text] [Related]
10. Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer.
Netzel BC; Grebe SK
Clin Chim Acta; 2013 Oct; 425():1-2. PubMed ID: 23832066
[TBL] [Abstract][Full Text] [Related]
11. Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR.
Carotenuto P; Roma C; Cozzolino S; Fenizia F; Rachiglio AM; Tatangelo F; Iannaccone A; Baron L; Botti G; Normanno N
Int J Oncol; 2012 Feb; 40(2):378-84. PubMed ID: 21971641
[TBL] [Abstract][Full Text] [Related]
12. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.
Molinari F; Felicioni L; Buscarino M; De Dosso S; Buttitta F; Malatesta S; Movilia A; Luoni M; Boldorini R; Alabiso O; Girlando S; Soini B; Spitale A; Di Nicolantonio F; Saletti P; Crippa S; Mazzucchelli L; Marchetti A; Bardelli A; Frattini M
Clin Cancer Res; 2011 Jul; 17(14):4901-14. PubMed ID: 21632860
[TBL] [Abstract][Full Text] [Related]
13. Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization.
Ausch C; Buxhofer-Ausch V; Oberkanins C; Holzer B; Minai-Pour M; Jahn S; Dandachi N; Zeillinger R; Kriegshäuser G
J Mol Diagn; 2009 Nov; 11(6):508-13. PubMed ID: 19797612
[TBL] [Abstract][Full Text] [Related]
14. The importance of evaluation of DNA amplificability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues.
Okayama N; Nishioka M; Hazama S; Sakai K; Suehiro Y; Maekawa M; Sakamoto J; Iwamoto S; Kato T; Mishima H; Oka M; Hinoda Y
Jpn J Clin Oncol; 2011 Feb; 41(2):165-71. PubMed ID: 20926413
[TBL] [Abstract][Full Text] [Related]
15. Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients.
Taniguchi H; Yamazaki K; Yoshino T; Muro K; Yatabe Y; Watanabe T; Ebi H; Ochiai A; Baba E; Tsuchihara K;
Cancer Sci; 2015 Mar; 106(3):324-7. PubMed ID: 25800101
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology.
Perez K; Walsh R; Brilliant K; Noble L; Yakirevich E; Breese V; Jackson C; Chatterjee D; Pricolo V; Roth L; Shah N; Cataldo T; Safran H; Hixson D; Quesenberry P
Exp Mol Pathol; 2013 Aug; 95(1):74-82. PubMed ID: 23528430
[TBL] [Abstract][Full Text] [Related]
17. High sensitive mutation analysis on KRAS gene using LNA/DNA chimeras as PCR amplification blockers of wild-type alleles.
Huang Q; Wang GY; Huang JF; Zhang B; Fu WL
Mol Cell Probes; 2010 Dec; 24(6):376-80. PubMed ID: 20732413
[TBL] [Abstract][Full Text] [Related]
18. Challenges posed to pathologists in the detection of KRAS mutations in colorectal cancers.
Dudley J; Tseng LH; Rooper L; Harris M; Haley L; Chen G; Gocke CD; Eshleman JR; Lin MT
Arch Pathol Lab Med; 2015 Feb; 139(2):211-8. PubMed ID: 25611103
[TBL] [Abstract][Full Text] [Related]
19. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
Heideman DA; Lurkin I; Doeleman M; Smit EF; Verheul HM; Meijer GA; Snijders PJ; Thunnissen E; Zwarthoff EC
J Mol Diagn; 2012; 14(3):247-55. PubMed ID: 22425762
[TBL] [Abstract][Full Text] [Related]
20. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
